The Liver kinase B1 with its downstream target AMP activated protein kinase (LKB1-AMPK), and the key nutrient sensor mammalian target of rapamycin complex 1 (mTORC1) form two signaling systems that coordinate metabolic and cellular activity with changes in the environment in order to preserve homeostasis. For example, nutritional fluctuations rapidly feed back on these signaling systems and thereby affect cell-specific functions. Recent studies have started to reveal important roles of these strategic metabolic regulators in Schwann cells for the trophic support and myelination of axons. Because aberrant intermediate metabolism along with mitochondrial dysfunction in Schwann cells is mechanistically linked to nerve abnormalities found in acquired and inherited peripheral neuropathies, manipulation of the LKB1-AMPK, and mTORC1 signaling hubs may be a worthwhile therapeutic target to mitigate nerve damage in disease. Here, recent advances in our understanding of LKB1-AMPK and mTORC1 functions in Schwann cells are covered, and future research areas for this key metabolic signaling network are proposed.
Introduction
The study of cellular metabolism is currently regaining the attention of the biomedical research community. There is now an increasing perception that metabolism is not simply a dull collection of self-regulatory biochemical pathways, but a central determinant of all biological outputs with extensive implications for understanding physiology and disease. In contrast to earlier concepts in which the phenotype of a cell or tissue simply relays information to metabolic pathways to obtain the necessary metabolites and energy to function, accumulating evidence indicates that instead such pathways or even individual metabolites can shape divergent biological outcomes with regard to proliferation, growth, differentiation, intercellular interactions, and immune responses (e.g., [1] [2] [3] [4] [5] ). This may be most notably seen in present cancer research with the prevailing view that reprogramming of intermediate metabolism by oncogenic signals drives tumor initiation and progression, and suppression of these pathways has the potential to inhibit tumorigenesis and growth. [6] Thus, understanding how specific metabolic processes influence cellular function may offer novel therapeutic approaches for a broad range of pathological conditions.
The question as to how metabolism impacts biological output can be best illustrated in context of energy and nutrient sensing: before a cell commits to any particular biological function, there must be dynamic mechanisms in place to evaluate whether there are sufficient energy and nutrient levels (sugars, amino acids, lipids) available. If so, cells also require the potential to rapidly and efficiently reprogram their metabolic state to meet the rising demands of functional change. These general principles and the recent renaissance in metabolism research have uncovered intriguing relationships between intracellular signal transduction and metabolic pathways. It is now clear that energy, oxygen, and nutrient sensors are incorporated in strategically positioned regulatory enzyme complexes including sirtuins, the LKB1-AMPK kinases, mammalian target of rapamycin complex 1 (mTORC1), and the hypoxia-inducible-factor-1α (HIF1α) pathway, that couple intermediate metabolism to cellular function. [7] [8] [9] [10] [11] In other words, these sensors are interfaced with the cellular signal transduction network to interact with metabolic pathways on an integrative level to adjust metabolism to phenotype and vice versa. The dysregulation of such holistic controllers constitutes a pernicious environment, ultimately increasing the predisposition for widespread chronic diseases such as obesity, diabetes, cardiovascular conditions, and neurodegeneration. Thus, the effects of metabolic derailments appear further reaching than previously assumed, likely extending to biological systems and disease phenotypes that traditionally have not been linked to aberrant metabolism.
Why Study Metabolism in Schwann Cells?
Schwann cells (SCs) are highly specialized glial cells that are directly associated with long axons of neurons. They are the most abundant cell type in the peripheral nervous system (PNS) and are primarily appreciated for regulating various aspects of axonal function, most notably insulating axons and increasing the speed at which electrical nerve impulses propagate along nerve fibers. [12] The importance of studying metabolic regulation in SCs is emphasized by the following feats of this fascinating cell type.
During PNS development, SC precursors rapidly proliferate, and then produce extraordinary amounts of membrane extensions upon contact with growing axons during a relatively short postnatal time window. This is a tightly regimented process, and eventually the spiral wrapping of these membrane extensions around axons results in the formation of unique compact myelin sheaths rich in lipids. While work from the last decade has uncovered important growth factor mechanisms responsible for these SC biosynthetic functions, [13] the role of energy and nutrient provision during these processes is largely unknown. A broad recapitulation of these developmental features, albeit with many molecular differences, occurs after nerve damage in adulthood, when SCs proliferate after losing contact with degenerating axons, and then re-myelinate newly formed axons. [14] SC proliferation in itself introduces important problems for cellular metabolism because each passage through the cell cycle requires a doubling of total biomass and thus an abundance of energy and biosynthetic precursors. Together with the more than 1000-fold increases in membrane area necessary for myelin sheath production, [14] these processes present profound metabolic challenges for SCs that must be met during the establishment of nerves. It is clear that regulatory mechanisms that promote and later restrict anabolic pathways would be highly active in proliferating and myelin-producing cells. How nutrient input and metabolic regulation influence SC proliferation and myelin formation remains largely unexplored.
Another important rationale for studying metabolism in SCs is mounting evidence that energy metabolism in axon-flanking glial cells of the central nervous system (CNS) (i.e., oligodendrocytes and astrocytes) is closely linked to neuronal metabolism. This metabolic crosstalk ensures nervous system stability under varying conditions of neuronal activity and stress ("neurometabolic coupling"). A topical concept derived from the still controversial neuron-astrocyte lactate shuttle [15, 16] is that oligodendrocytes, the myelinating glia of the CNS, are similarly metabolically coupled to long axons by supplying small metabolites, including pyruvate and lactate, that are used to fuel axonal energetic needs. [17] [18] [19] Axons in the PNS are likely also dependent on the metabolism of their SC glia as a source of energy, especially when functionally challenged or distressed. [20, 21] Disruption of such metabolic cellular crosstalk would be expected to lead to axonal degeneration, thus compromising neuronal connectivity. This model is especially appealing in light of the emerging concept that energetic crisis underlies recently delineated molecular pathways of axon death. [22, 23] Indeed, meeting energetic requirements is a crucial factor in axonal maintenance for at least two reasons. Axons are extremely long structures with enormous membrane surface areas, their volume exceeding that of the neuronal cell body by roughly 1000-fold in a typical motor neuron. [24] This maintenance challenge, coupled with the need to constantly sustain axonal transport as well as ion gradients along axons, translates to very high metabolic demand. One recent study, based on electrophysiological and neuropharmacological experiments, proposed that lactate derived from glycogen stores in SCs supports axonal energy metabolism in analogy to glycogen breakdown and lactate shuttling from astrocytes to CNS axons. [25] Perturbations of SC metabolism likely contribute to the etiology of axonal degeneration and myelin abnormalities in neuropathies secondary to diabetes mellitus. [26] [27] [28] [29] [30] [31] Diabetic neuropathy (DN) is the most prevalent peripheral neuropathy of all, occurring in about half of all diabetes mellitus patients. [32] The histopathological changes in DN nerve biopsies are dominated by the early loss of unmyelinated, and later degeneration of myelinated axons, which is denoted by the term "small fiber sensory neuropathy." [31, 32] Thus, small sensory fibers under DN conditions are more vulnerable to degeneration than motor axons, possibly as a result of increased axonal energy consumption due to the lack of the myelin sheath (note that the myelin sheath decreases axonal energy consumption through enabling saltatory nerve conduction, and thus reduces the need to maintain ion gradients, etc.). This would indicate a greater dependence of small unmyelinated axons on SC bioenergetics support. The higher vulnerability may also result from other biophysical characteristics of unmyelinated or only thinly myelinated axons that need to be supported by SCs (e.g., differential cytoskeletal configuration that affects axon stability). [29] Moreover, the much smaller size of unmyelinated axons suggests that their vulnerability may arise from accumulation of toxic metabolites, which would lead to much higher concentrations in small axons owing to their lower axoplasmic volume. In parallel, and independent from the considerations about axonal degeneration, early abnormalities in myelination have been documented in DN, for example suggesting cycles of demyelination and aberrant re-myelination of still intact axons in the PNS. [31, 32] Additionally, there are reports about abnormal proliferative responses associated with perturbed intracellular mitogenic signaling in SCs as a consequence of sustained hyperglycaemia resulting in SC differentiation deficits. [31, 32] Despite these insights, the role of the SC in the etiology of DN has received stepmotherly treatment in recent decades. However, the model supporting that perturbations of SC metabolism by hyperglycaemia, dyslipidaemia, aberrant insulin signaling, and other systemic abnormalities evoke differentiation abnormalities and release of toxic intermediates from SCs among other irregularities is now a subject of reinvigorated interest. [29, 31] Taken together, from a comprehensive standpoint it is intuitive to assume that the control of metabolic homeostasis is crucial for the diverse functions of SCs in the PNS. Misfits in metabolic demand and supply resulting in aberrant biological output of glia likely contribute to many abnormalities seen in neurodegenerative conditions such as DN. Despite this revelation, the effects of metabolic dysregulation in SCs on nerve function and structure are remarkably understudied.
The LKB1-AMPK and mTORC1 Signaling Hubs as Central Regulators of Metabolic Homeostasis
Extensive research over the past two decades has revealed that the orchestration of metabolic homeostasis is largely coordinated by two strategically positioned signaling hubs that sense cellular energy as well as nutrient levels ( Figure 1) . Intriguingly, a yin-yang-like antagonistic mechanism that balances catabolic and anabolic pathways comprises the Liver kinase B1 (LKB1) À AMP-activated kinase (AMPK) system on one side, and the antipode mammalian target of rapamycin (mTOR) complex 1 (mTORC1) on the other (Zhang et al., [33] reviewed in refs. [8, 34, 35] ). These inversely regulated signaling centers adjust metabolism dynamically to adapt to rapidly fluctuating microenvironments, and also balance metabolism in a sustainable manner in order to confer long-term changes through gene regulation. Recent attention has focused on the discovery that both signaling hubs can be found in close proximity, and use the lysosome as a platform for energy/nutrient sensing as well as signaling to pathways such as autophagy. [8, 33, [36] [37] [38] Lysosomes can be regarded as storage and resorption sites for amino acids (aa), carbohydrates and lipids, similar to an organismal intestinal system. [8] This localization allows both signaling systems to gauge the nutrient status of the cell and rapidly shift their activities to maintain homeostasis. The LKB1-AMPK nexus functions as part of an evolutionary conserved complex that senses cellular ATP and glucose levels, [8, 36] whereas mTORC1, together with its co-factors, predominantly senses levels of aa, possibly by proxy of concentrations of individual aa measured at lysosomes. [7, 39] As a general principle, the metabolic checkpoint imposed by LKB1-AMPK is activated in energy and nutrient deplete conditions when mTORC1 is concomitantly inactive, while under energy rich and nutrient replete conditions mTORC1 activity is induced and LKB1-AMPK in turn is deactivated ( Figure 1 ). [34, 35, 40] Active mTORC1 stimulates an extensive anabolic network including the protein, lipid, and nucleotide synthesis apparatus that consumes vast proportions of ATP. [7, 41, 42] At the same time, mTORC1 inhibits catabolic processes such as autophagy. [43, 44] In contrast, the active LKB1-AMPK hub switches on catabolic pathways that generate ATP such as uptake and oxidative consumption of glucose and fatty acids, while simultaneously limiting the ATP-consuming anabolic pathways mentioned above. [45, 46] Under energy deprivation conditions, the net result of LKB1-AMPK activation is the conservation of cellular energy before the cell reaches a state of bioenergetics crisis. Thus, the LKB1-AMPK system can be regarded as a "protective shield" for the mTORC1 "engine" that promotes many anabolic functions driving cell growth and proliferation. Figure 1 . Regulation of metabolic homeostasis by the LKB1-AMPK and mTORC1 signaling hubs through balance between anabolism and catabolism. Schematic illustrating antagonistic regulation of catabolic and anabolic cellular pathways by the LKB1-AMPK and mTORC1 signaling systems (main components shown). LKB1-AMPK signaling is promoted by energy/nutrient depletion, whereas mTORC1 signaling is facilitated by energy/nutrient sufficiency. Both growth factor/mitogen and nutrient (amino acids, glucose) inputs together determine mTORC1 activation.
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LKB1-AMPK Signaling
LKB1 is a phylogenetically conserved and ubiquitously expressed serine-threonine kinase (encoded by the Stk11 gene) that was first identified as tumor suppressor, and is now widely accepted as such in different cell types. [47, 48] Current evidence suggests that LKB1 is constitutively active, not substantially regulated by stimuli from any other upstream kinase. [49] Thus, it appears that LKB1 exerts its functions based on substrate availability. The quest for downstream targets of LKB1 resulted in the identification of the serinethreonine kinase AMPK as an LKB1 phosphorylation substrate, [45, 50] and at least 13 AMPK-related kinases (ARKs) involved in the regulation of intermediary metabolism and, perhaps as a direct consequence of this regulation, many other biological functions (e.g., cell polarity). [51] [52] [53] [54] [55] Because much less is known about ARK functions, the multifaceted metabolic actions of LKB1 are often attributed solely to AMPK, which phosphorylates an evergrowing list of downstream metabolic enzymes, transcription factors, and co-activators. [46, 56] However, in the hematopoietic system, LKB1 appears to sustain metabolic homeostasis through downstream ARKs largely independent of AMPK. [57] [58] [59] Similarly, LKB1 functions independently from AMPK to maintain metabolism in regulatory Tcells, and rather acts through the salt inducible kinases (SIKs) or MAP/microtubule affinity-regulating kinases (both belonging to the ARKs). [60] [61] [62] In the liver, LKB1 suppresses gluconeogenesis in hepatocytes also through the SIKs, independent from AMPK. [63, 64] Last mentioned, while promoting AMPK activity, in general, appears to restrain tumorigenesis, AMPK seems to exert the metabolic tumor suppressor functions of LKB1 only partially, and paradoxically seems to be activated despite LKB1 deficiency in some circumstances. [45, 65] Yet, a well-established and elementary function of LKB1 is to sense and restore cellular ATP levels via AMPK. [46] LKB1 directly phosphorylates and activates AMPK in response to rising AMP:ATP ratios reflecting attenuated cellular energy charge. [46] The key molecular step in the LKB1-mediated activation of AMPK is its phosphorylation on threonine 172 (T172) within the T-loop of its catalytic α subunit, a process that is greatly amplified by binding of AMP to the γ subunit of AMPK (note that AMPK forms a heterotrimeric complex with a catalytic α subunit, and two regulatory subunits β and γ). [46] This allosteric mechanism is highly conserved across species, and increases the kinase activity of AMPK more than 100-fold. [46] The activated AMPK complex containing the T172-phosphorylated α subunit elicits a plethora of downstream alterations such as the phosphorylation of the metabolic enzymes acetyl-CoA carboxylase 1 (ACC1) and HMG-CoA reductase (HMGCR). [66] These modifications inhibit fatty acid and cholesterol biosynthesis, respectively, and thus conserve ATP. Conversely, activated LKB1-AMPK promotes glycolysis, the tricarboxylic acid cycle, fatty acid oxidation, and mitochondrial respiration, and therefore ATP production, by phosphorylating key regulatory factors such as 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB), acetyl-CoA carboxylase 2 (ACC2), and peroxisome proliferatoractivated receptor-γ coactivator-1 α (PGC1α). [46] One of the most prominent but sometimes overlooked catabolic pathways positively regulated by LKB1-AMPK is autophagy. [43, 67] In addition to being a major degradation pathway, autophagy is activated when cellular nutrient levels are low to generate ATP and restore pools of aa and other nutrients by extracting recycled substrates from autophagosomes. AMPK promotes autophagy to a great extent by regulating the activity of the autophagy-initiating kinase ULK1 through phosphorylation on multiple sites. [46] Finally, intertwined with its pleiotropic metabolic effects, the LKB1-AMPK system alters multiple cellular aspects, such as cell polarity, shape, and mechanotransduction, functions that are mechanistically tightly linked to the metabolic configuration of a cell because of its potential to modulate energy consumption. [53, [68] [69] [70] 3.2. mTORC1 Signaling mTORC1 is a multiprotein complex comprising the mammalian target of rapamycin (mTOR) core kinase (a serine/threonine kinase), the substrate-guiding protein Raptor (regulatory protein associated with mTOR), and an ensemble of other proteins with modulatory functions. [7, 40, 41] The mTOR core kinase also associates with a different substrate guiding protein, Rictor (rapamycininsensitive companion of mTOR), in the related complex mTORC2 (mammalian target of rapamycin complex 2). [7, 41] Compared to mTORC1, the function and regulation of mTORC2 is much less well understood but has been demonstrated to influence cell survival and the cytoskeleton. [7, 41] mTORC1 is often described as a major signaling integrator of diverse growth factors and mitogenic input that impinge on the PI3K/AKT and MAPK pathways, most notably the insulin/insulin-like growth factor-1 (IGF-1) pathway. [40, 41] This regulation occurs through the AKT-or ERK-mediated inhibitory phosphorylation and subsequent lysosomal removal of the tuberous sclerosis complex 2 (TSC2) protein, a key inhibitor of mTORC1 ( Figure 2) . [7, 41] Thus, induction of the PI3K/AKT and MAPK pathways releases mTORC1 from TSC2-mediated inhibition. TSC2 functions as a GTPase activating protein (GAP) that hydrolyzes Rheb-GTP to Rheb-GDP. [7, 41] Rheb (RAS-homolog enriched in brain), a small GTPase, is an immediate activator of mTORC1, but promotes mTORC1 only when bound to GTP. [7, 41] Under conditions of growth factor withdrawal, TSC2 is active and localized at the lysosome, thus promoting accumulation of Rheb-GDP, which curtails mTORC1 kinase activity (Figure 2 ). In addition to growth factors, nutrients are equally important for enhancing mTORC1 activity. [39, 40] For this reason, mTORC1 has been compared to a molecular "AND gate," requiring both the presence of nutrients and growth factors/mitogens for its maximum activation (Figure 2) . [7, 39, 40] However, nutrient signals dominate as a requirement for mTORC1 activation, because growth factors fail to activate mTORC1 in the absence of nutrients. [71] How nutrients, especially aa, regulate mTORC1 has only recently started to be understood, and the respective mechanisms seem to largely converge on activation of the small Rag GTPases RagA or RagB at the lysosomal surface. [39] The presence of aa converts these GTPases to their active GTPbound state (and converts their heterodimeric binding partners RagC/D to the GDP-bound form), which allows RagA/B to bind Raptor and recruit mTORC1 to Rheb located on the lysosome (Figure 2) . [39] There is also recent evidence that glucose and cholesterol promote RagA/B GTP loading and mTORC1 lysosomal recruitment. [72, 73] Under optimal nutrient and trophic conditions, GTP-loaded Rheb binds and activates mTORC1 and results in the subsequent phosphorylation of a multitude of anabolic mTORC1 substrates. For example, mTORC1 promotes protein synthesis mainly through the phosphorylation of S6 Kinases (S6K1 and 2) and www.advancedsciencenews.com www.bioessays-journal.com eIF4E Binding proteins (4EBP1 and 2), and lipid synthesis through regulation of the sterol responsive element binding proteins (SREBPs). [7, [74] [75] [76] Cell growth and proliferation also require an abundant supply of purines, pyrimidines, and ribosomes, as well as the induction of the oxidative arm of the pentose phosphate pathway (PPP). The molecular mechanisms underlying mTORC1-dependent purine/pyrimidine nucleotide biosynthesis have been recently elucidated, [77, 78] and mTORC1 has also been shown to promote glycolysis and the PPP to generate NADPH and other essential intermediates needed for the support of macromolecule synthesis. [7, 40] Similar to all the other reciprocal relationships, while the LKB1-AMPK system promotes autophagy, mTORC1 suppresses autophagy. [7, 43, 44] Under nutrient rich conditions, mTORC1 phosphorylates the gatekeeper kinase ULK1 at different sites than LKB1-AMPK and thereby prevents its activation antagonistically. [43, 44] Furthermore, mTORC1 directly phosphorylates and inhibits the transcription factor EB (TFEB) and other autophagy components, the former a master regulator of lysosomal and autophagy genes. [75, 79, 80] Thus, the relative activities of mTORC1 and LKB1-AMPK in the cell at any given time determine autophagic activity.
The LKB1-AMPK system primarily uses signaling mechanisms to directly inhibit mTORC1, when the levels of ATP are low, in order to prevent energetic misbalance. AMPK activates the TSC2 protein by way of phosphorylation on serine/threonine residues, which inhibits Rheb GTP loading, and renders mTORC1 inactive (Figure 2) . [81] Additionally, LKB1-AMPK suppresses the mTORC1 kinase activity by phosphorylating Raptor. [82] Active LKB1-AMPK also antagonizes mTORC1 effectors on several downstream levels, in addition to the above-described effects on autophagy via ULK1. For example, AMPK phosphorylates and inhibits SREBPs, [83] and it can restrain peptide chain elongation during mTORC1-promoted mRNA translation by inhibiting the eukaryotic elongation factor (eEF2). [84] A plethora of additional crosstalk mechanisms between LKB1-AMPK and mTORC1 have been documented in many in vitro studies, [34, 35, 38] but their relevance in vivo remains unclear.
Perinatal LKB1 Disruption in SCs Impairs Myelination
The role of LKB1 in SCs has been studied recently by three independent groups using conditional mouse mutagenesis approaches, but with different perspectives, scopes, and Figure 2 . Regulation of mTORC1 activity by growth factors, nutrients, and energetic status. Simplified schematic illustrating coordinate spatial regulation of TSC2 and mTORC1 at the lysosomal surface by growth factor signaling and nutrient/energy availability, respectively, and thus control of overall mTORC1 signaling output. In presence of growth factors, TSC2 (a GTPase activating protein, GAP) dissociates from the lysosomal surface (e.g., promoted by phosphorylation of TSC2 by AKT), which prevents it from suppressing GTP-loading of Rheb. This permissive condition enables activation of mTORC1 by the active GTPase Rheb (GTP loaded) at the lysosome when nutrients are available. Withdrawal of nutrients leads to inactivation of the GTPases RagA/B (GDP loaded) which are no longer able to recruit mTORC1 to the lysosome. This results in mTORC1 deactivation, even in presence of growth factors. Energetic deficiency stimulates AMPK which regulates TSC2 localization antagonistically to growth factors signaling (i.e., recruitment to the lysosomal surface vs. removal) through phosphorylation. Note that RagA/B is tethered to the lysosome through the pentameric Regulator complex, which functions as a guanine nucleotide exchange factor for RagA/B. Rheb is directly anchored to the lysosomal membrane.
www.advancedsciencenews.com www.bioessays-journal.com objectives. [85] [86] [87] [88] Whereas the emphasis in two of these studies was to investigate the impact of LKB1 ablation on PNS nerve development and myelination, [86, 87] Beirowski et al. primarily focused on the glial functions of LKB1 that are essential for the support of axon integrity. [85] Moreover, Shen et al. considered exclusively the involvement of LKB1 in regulation of SC polarity, [87] while the other studies concentrated on the functions of LKB1 as a metabolic regulator in SCs. [85, 87] Perinatal conditional deletion of the LKB1/Stk11 gene in SC precursors in vivo was achieved by using mutant mice carrying floxed LKB1/ Stk11 alleles (LKB1 flox/flox ) and a P0-Cre transgene, [85] or a CNPCre knock in allele, [86, 87] both of which result in early expression of Cre recombinase in the SC lineage (starting at %E13.5 for P0-Cre and %E12 for CNP-Cre). [85] [86] [87] Although each study documented a delay in the initiation of myelination accompanied by SC differentiation abnormalities, followed by hypomyelination (thinner myelin sheaths) in adulthood, [85] [86] [87] it is remarkable that adult LKB1 flox/flox À P0-Cre mice showed a gradual reversal of these deficits. [85] This recovery presumably reflects compensatory effects conferred by upregulation of critical myelination factors such as Egr2 and the neuregulin receptor pair ErbB2/B3 in these mutants. Additionally, the early attenuation of nerve development appears to be more severe in LKB1 flox/flox À CNP-Cre mutants, resulting in greatly reduced nerve size, debilitating neurological deficits, and a prominent growth retardation phenotype (and unpublished observations, Figure 3 ). [86, 87] It is possible that the earlier expression of Crerecombinase and higher recombination efficiency as well as haploinsufficiency of the myelin component CNP (2 0 , 3 0 -Cyclic nucleotide 3 0 -phosphodiesterase) in LKB1 flox/flox À CNP-Cre mutants account for these differences. The dysmyelination resulting from LKB1 depletion in SCs was recapitulated in coculture in vitro systems in which LKB1 was selectively depleted in developing SCs, associated with dorsal-root-ganglion (DRG) axons, employing adenoviral/retroviral systems. [86, 87] Curiously, completely different underlying mechanisms for the deficiencies in nerve development and myelination were proposed in the two reports studying the LKB1 flox/flox À CNP-Cre and co-culture myelination models. [86, 87] In one report, consistent with the previously reported roles of LKB1 to promote mitochondrial homeostasis, [57] [58] [59] [60] [61] Pooya et al. found that differentiating LKB1-deficient SCs showed compromised mitochondrial activity, and were incapable of switching from glycolytic to a predominantly mitochondrial oxidative metabolism during nerve development, a metabolic conversion that was hypothesized to be required for normal myelination. [86] This was accompanied by decreased activity of the Krebs cycle enzyme citrate synthase, resulting in an attenuated production of the intermediate citrate, a facultative precursor of myelin lipids. [86] As a result, lipidomic analysis showed reduced content of all major myelin lipid classes in nerve preparations from LKB1 flox/flox À CNP-Cre mutants, suggesting this lipid synthesis deficit accounts for the dysmyelination. [86] In the second report, Shen et al. found that regardless of any metabolic functions, LKB1 deletion in SCs compromises the proper localization of the critical cell polarity protein Par-3, which has been previously proposed to be important for myelination in an in vitro co-culture system. [89] However, given that the in vivo functions of Par-3 and other polarity components in SCs are likely redundant, [87, 90, 91] it is conceivable that abnormal localization of Par-3 may have arisen because of the metabolic abnormalities in crippled SCs, and Par-3 inactivation, per se, does not contribute to the dysmyelination observed. In this respect, it would be important in the future to characterize nerve development and myelination in conditional mutants lacking Par-3 in SCs.
LKB1 Inactivation in SCs Leads to Axon Degeneration
Remarkably, the much milder dysmyelination phenotype in LKB1 flox/flox À P0-Cre mice helped to unveil another, perhaps even more important myelin-independent function of LKB1 in SCs, namely to promote the glial metabolic support functions requisite for maintenance of axon integrity. [85, 88] The identification of this novel role of glial LKB1 is based on the observation that LKB1
flox/flox À P0-Cre mice develop progressive degeneration of both unmyelinated and myelinated axons starting at around 3 months of age. [85] Importantly, and consistent with the gradual recovery from the developmental dysmyelination, LKB1
flox/flox À P0-Cre mutants show no changes in SC viability, and no signs of concomitant demyelination and neuroinflammation as the axon degeneration progresses. To further separate the axonal degeneration phenotype mechanistically from myelination defects due to aberrant nerve development, LKB1 was deleted from mature SCs in adult animals expressing the conditional LKB1 alleles and a tamoxifen-inducible PLP-Cre ERT transgene. [85] Alike the LKB1 flox/flox À P0-Cre mice, these mutants manifested axon degeneration, but this occurred in the presence of normal myelination. This finding also suggests that LKB1 is dispensable for myelin maintenance, but essential for long-term axon support by virtue of its metabolic functions. [85] Intriguingly, in both animal models the progressive axonopathy preferentially affected small diameter axons including unmyelinated fibers organized in structures known as Remak bundles, while large diameter myelinated axons were relatively spared. [85] Similarly, prominent Remak bundle axon degeneration can be also observed in LKB1 flox/flox À CNP-Cre mice (unpublished, Figure 3 ). This propensity toward degeneration of small diameter fibers is reminiscent of the neuropathology observed in DN. In fact, the LKB1 flox/flox À P0-Cre mutants also displayed extensive axon degeneration in the vagus nerve (which contains mostly small parasympathetic, unmyelinated fibers), mimicking an important feature of the autonomic component of DN. Evidence for the notion that the axon degeneration in the LKB1 mutants is secondary to failed metabolic support functions in SCs came from studies employing a range of metabolic analyses and interventions using LKB1-depleted nerves or isolated mutant SCs. With respect to carbohydrate metabolism, an untargeted metabolomics approach followed by more conventional biochemical measurements, revealed elevated lactate release from LKB1-deficient SCs. [85] This was initially a somewhat surprising result in light of the proposed beneficial effects of glial lactate required for axon maintenance. [25, [92] [93] [94] However, pharmacological experiments attempting to decrease the augmented lactate release by administration of 2-Deoxy-D-glucose (2-DG) suggested that this lactate adaptation in mutant SCs indeed supports axons in
LKB1
flox/flox À P0-Cre nerves, since 2-DG treated mutant nerves showed exacerbated axon degeneration. [85] Together, these data support the model that such axons are deteriorating as a consequence of dysregulation of other metabolic pathways in mutant SCs, and the increased production and secretion of lactate in SCs lacking LKB1 may occur as a general neuroprotective response of SCs to axonal injury (Figure 4, middle) . In fact, impaired mitochondrial metabolism in LKB1 flox/flox À P0-Cre nerves was supported by progressively decreasing ATP concentrations, NAD þ /NADH ratios, and cytochrome oxidase enzyme activity, despite dramatically increased SC mitochondrial mass associated with defective mitophagy. [85] Further experiments using isolated LKB1-deficient SCs from aged animals demonstrated aberrant mitochondrial membrane potential and elevated production of reactive oxygen species (ROS). [85] Given the known functions of mitochondria in maintaining lipid homeostasis, and consistent with the aberrant nerve lipid metabolism reported in Pooya et al., [86] a shotgun lipidomics screen demonstrated dramatically reduced levels of major myelin lipids in nerves from 2-months-old LKB1 flox/flox À P0-Cre mice, while some lipid intermediates were moderately elevated. [85] Together, these data suggest that LKB1 deficiency in mature SCs promotes the accumulation of dysfunctional mitochondria that may lead not only to energetic failure, but also to secondary detrimental effects such as ROS generation and aberrant SC lipid metabolism. These pathological features are all likely to compromise axonal health.
A key question is how glial LKB1 exerts its functions in terms of downstream signaling to support axons metabolically. In order to address if LKB1 deletion in SCs results in axon degeneration via inactivation of its prime energy-sensing target AMPK, different mouse lines with constitutive and conditional elimination of individual AMPK subunits leading to complete inactivation of AMPK enzymatic activity in SCs were generated. [85] No axon degeneration could be observed in these mutants despite the occurrence of myelin abnormalities in aged animals. This suggests the surprising conclusion that AMPK in SCs is dispensable for axonal support, but perhaps important for www.advancedsciencenews.com www.bioessays-journal.com long-term myelin maintenance. However, the age-dependent development of the myelin abnormalities may also be due to the systemic ablation of individual AMPK subunits that are known to influence whole body metabolism, including lipid metabolism. [95] Future studies using mutant mice with AMPK deactivation exclusively in SCs will therefore be necessary to explore the role of AMPK for myelin maintenance. Counterintuitively, however, additional experiments led to the finding that AMPK activity is markedly increased in SCs from LKB1 flox/flox À P0-Cre nerves, despite the LKB1 deletion (Beirowski et al. [85] and unpublished). This is consistent with the observed energetic depletion and promotion of catabolic pathways including glycolysis and lactate release in these nerves, and suggests that AMPK can be activated via LKB1-independent mechanisms. Accordingly, LKB1
flox/flox À P0-Cre nerves showed pronounced hyperactivation of the MAP3 kinase TAK1, [85] which is known to phosphorylate and induce AMPK independently from LKB1 in certain contexts. [96] [97] [98] The TAK1-AMPK activation in LKB1-deficient SCs could be therefore viewed as a cytoprotective compensatory response to support distressed axons via increased lactate release (Figure 4, middle) . Alternatively, it could be also speculated that the hyperactivated TAK1-AMPK axis in LKB1-deficient SCs may contribute to the aberrant glial metabolism that leads to axon degeneration, potentially trough release of toxic factors (Figure 4, right) . In addition to a mechanism implicating TAK1-AMPK, it is also conceivable that metabolic alterations secondary to differentially regulated ARKs or other key metabolic targets (e.g., Hif1α) [99] account for the axon degeneration observed in LKB1 flox/flox À P0-Cre nerves (Figure 4 ). Future studies are therefore warranted to explore the roles of the abnormally induced TAK1 and AMPK enzymes, and characterize the expression and activation status of individual ARKs and other substrates in LKB1-deficient SCs.
mTORC1 Promotes Schwann Cell Proliferation or Myelinogenesis, Depending on Context
Preliminary evidence for the role of mTORC1 as the key driver of myelin growth in the PNS came with the discovery of a hypomyelination phenotype in mutant mice in which the mTOR core kinase has been ablated in SC precursors. [100] Subsequently, mutant mice with elimination of Raptor in SC precursors were developed, and this pinpointed mTORC1 inactivation as causal for the arrest of myelination owing to its prime functions for lipid and protein biosynthesis. [101] The consequences of mTORC1 inactivation on already established myelin sheaths in mature SCs remain unknown, but given that PNS myelin likely undergoes turnover and that myelin synthesis continues into adulthood, [102] it is natural to hypothesize that continuous mTORC1 activity is required for maintenance of a normal biochemical myelin composition and myelin sheath geometry. Notably, mTOR ablation in SCs has been initially linked to perturbations in axonal cytoskeleton composition, suggesting axonal destabilization Figure 4 . Potential mechanisms underlying axon degeneration secondary to LKB1 inactivation in SCs. A) Schematic illustrating model for long-term glial axon support under basal conditions by AMPK-independent LKB1 signaling in SCs. Instead involving AMPK, the maintenance of metabolic homeostasis in SCs important for support of axonal health occurs through AMPK-related kinases (ARKs) or other LKB1 substrates. B) Such SC metabolic homeostasis is perturbed due to the absence of LKB1, and the subsequent dysregulation of ARKs and other LKB1 targets may directly lead to axonal stress and damage (left). Under such conditions of axonal stress, the induction of AMPK activity by upstream TAK1 activation might confer acute support for distressed axons through promotion of glycolysis that results in elevated glial pyruvate/lactate release (right). C) By contrast, in an alternative model, the hyperactivities of TAK1 and AMPK could compromise metabolic homeostasis that might be detrimental to axonal health. The increased pyruvate/lactate release might occur independently from TAK1 and AMPK hyperactivities. The inactivation of LKB1 itself and the associated metabolic changes are not harmful to axons.
www.advancedsciencenews.com www.bioessays-journal.com resulting from the metabolic abnormalities evoked by mTORC1-deficiency in SCs. [100] This was especially significant in light of reduced mTORC1 activity in SCs from LKB1 flox/flox À P0-Cre nerves, indicating the possibility that this downstream alteration may be etiological for axon degeneration (note that hyperactive AMPK in LKB1-deficient SCs is expected to inhibit mTORC1 activity through TSC2 activation). [85] However, the additional characterization of SC-specific mTOR and Raptor knockout mice that showed no signs of axonal loss, regardless of age, indicated that mTORC1 activity in SCs is dispensable for axon maintenance [85] (and unpublished). Intriguingly, more recent studies uncovered rather unanticipated mTORC1 functions in the SC lineage that are essential to set the stage for normal nerve development. Despite the apparent role of mTORC1 to promote myelinogenesis inferred from the above loss-of-function studies (and several studies focusing on CNS myelination), it was then found that mTORC1 activity actually declines rapidly in SCs while glial differentiation and myelination proceeds. [102] [103] [104] This contradictory temporal pattern provided motivation to generate mice with disrupted tuberous-sclerosis-complex (TSC) complex components or upstream PTEN (phosphatase and tensin homolog) to induce different levels of sustained mTORC1 hyperactivity, in order to counteract the physiological mTORC1 decline in SC precursors during nerve development. The characterization of the developmental nerve phenotypes in these mutants led to the surprising conclusion that mTORC1 activity clearly impedes myelin formation by promoting the proliferation of immature SCs and blocking SC differentiation during nerve development. [103, 105, 106] This finding was subsequently confirmed by two other studies. [104, 107] Related molecular mechanisms for this function have been proposed including mTORC1-mediated control of cell cycle regulators such as p27 Kip1 and Polo-like kinases (PLKs), as well as the suppression of the transcription factor Egr2/Krox20 by hyperactive mTORC1-S6K signaling. [103, 104, 107] In stark contrast, induction of mTORC1 hyperactivity through TSC complex disruption in mature SCs that already established myelin, after nerve development is complete, led to aberrant myelin sheath overgrowth with no obvious impact on SC proliferation and differentiation. [103, 104, 107] Thus, these studies unveiled two diametrical functions of mTORC1 in the SC lineage, both of which manifest depending on the differentiation context of SCs. Because mTORC1 integrates both growth factor and nutritional cues, it will be of great importance in the future to understand the role of nutrient input for these two divergent functions of mTORC1 in SCs. As stated above, nutrient overload plays an important role in the pathogenesis of DN, and may account for many of the SC and myelin abnormalities that are characteristic for this type of neuropathy. Finally, mTORC1 superactivities in diabetic SCs may also contribute to non-cellautonomous axon damage, for instance through aberrant myelination. This idea is supported by the observation of extensive axon degeneration in conditional PTEN knockout mice with increased mTORC1 activity in SCs. [85] 
Conclusions
Considering that almost nothing was known about metabolic signaling hubs in SCs just a few years ago, significant progress has been made recently in identifying important functions of the LKB1-AMPK and mTORC1 signaling epicenters for SC biology. We now know that LKB1 acts as a crucial regulator of major metabolic pathways in SCs, which are central to their role in supporting axon integrity. Although AMPK activity in SCs seems to be dispensable for axonal support, it is still possible that an AMPK gain-of-function component in SCs lacking LKB1 is critical for understanding the mechanisms underlying metabolic support of PNS axons (Figure 4) . A key open question asks which metabolic pathways regulated by LKB1 in SCs are essential for axon support, and what the immediate downstream substrates of LKB1 are that control these pathways. With this respect, it is intriguing to note that a number of downstream ARKs have been recently implicated in maintenance of metabolic homeostasis in various cell types. [108, 109] On the other hand, dynamic mTORC1 regulation in SCs is now appreciated as a central orchestrator of glial biology. A key outstanding question for the future pertains to the role that nutrient input plays for the regulation of mTORC1 activity and thus mTORC1-dependent SC proliferation, differentiation, and myelination. Moving forward, it will be important in the context of disease to characterize changes in LKB1-AMPK and mTORC1 signaling that may develop in both acquired and inherited forms of peripheral neuropathies. Such alterations, if occurring early, may be a driver for axonal damage and myelin abnormalities. This raises the possibility that manipulation of the LKB1-AMPK and mTORC1 signaling hubs with the already established pharmacological paradigms (e.g., adopted from cancer research), could be harnessed to ameliorate axon degeneration and myelination abnormalities in disease.
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